鈥淎ccumulating evidence suggests that cancer stem cells are responsible for cancer initiation, progression, metastasis, recurrence, and drug resistance,鈥� said Jorge Moscat, Ph.D., program director of the Cell Death and Survival Networks Program at Sanford-Burnham. 鈥淥ur new research provides a better understanding of the signaling cascades that regulate stem cells and is essential for the design of new and more-efficacious therapies for cancer.鈥�
鈥淲e have shown that protein kinase C-zeta (PKC-zeta) normally inhibits stem cell activity through downregulation of two signaling pathways: beta-catenin and Yap,鈥� said Maria Diaz-Meco, Ph.D., senior co-author of the paper and professor in the Program. 鈥淧reviously, our lab showed that PKC-zeta acts as a tumor suppressor that maintains homeostasis of intestinal stem cells. The current study reveals the mechanism by which this occurs.鈥�
The intestine is covered by a single layer of epithelial cells that are renewed every 3 to 5 days. The pool of cells that replace these epithelial cells鈥攊ntestinal stem cells鈥攏eeds to be regulated to maintain homeostasis.
鈥淒isturbing the homeostasis of the stem cell pool can go two ways鈥攊t can either reduce intestinal epithelial cell regeneration or increase the proliferation of stem cells,鈥� said Diaz-Meco. 鈥淐ancer is produced by the accumulation of mutations in critical genes that control central mechanisms of cell growth. Stem cells are a 鈥榩ermanent鈥� population in the intestine and a reservoir for those mutations. Therefore, if stem cell activity is increased, as in the case of intestines deficient in PKC-zeta, then the likelihood of developing tumors is much higher, and when the tumor is initiated it becomes more aggressive.鈥�
Using a genetically engineered mouse model for intestinal cancer, the research team found that this process is kept under control by direct phosphorylation by PKC-zeta of two essential tumor promoters: beta-catenin and Yap.
鈥淚mportantly, we confirmed the tumorigenic profiles of PKC-zeta, beta-catenin, and Yap in human colon adenocarcinoma samples. The correlation of human results with our in-vivo mouse studies strongly suggests that Yap and beta-catenin are potential targets of PKC-zeta function and potential targets for new anti-cancer therapies.
"Our results offer new possibilities for the prevention and treatment of intestinal cancers by blocking the pathways that lead to tumors,鈥� said Moscat. "They also highlight a new strategy to promote intestinal regeneration after acute or chronic damage, such as that triggered by chemotherapy and radiation.鈥�
# # #
The study was performed in collaboration with the Biotechnology Centre of Oslo, University of Oslo, Norway.
This study was funded by NIH grants R01CA132847, R01CA172025, R01CA134530, and 5P30CA030199. Additional support was provided by Department of Defense grants W81XWH-13-1-0353 and W81XWH-13-1-0354.
ABOUT SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTESanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center, its NIH-designated Neuroscience Center Cores, and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs more than 1,000 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at .
Sanford-Burnham can also be found on Facebook at facebook.com/sanfordburnham and on Twitter .
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
; This study was funded by NIH grants R01CA132847, R01CA172025, R01CA134530, and 5P30CA030199.; Additional support was provided by Department of Defense grants W81XWH-13-1-0353 and W81XWH-13-1-0354.
RSS